Genome Sequencing is Critical for Forecasting Outcomes following Congenital Cardiac Surgery

- 3 4
- 5 W. Scott Watkins¹, E. Javier Hernandez², Thomas A. Miller³, Nathan R. Blue⁴, Raquel
- 6 Zimmerman², Eric R. Griffiths⁵, Erwin Frise⁶, Daniel Bernstein⁷, Marko T. Boskovski⁸,
- 7 Martina Brueckner^{9,10}, Wendy K. Chung¹¹, J. William Gaynor¹², Bruce D. Gelb¹³, Elizabeth
- 8 Goldmuntz¹⁴, Peter J. Gruber¹⁵, Jane W. Newburger¹⁶, Amy E. Roberts¹⁶, Sarah U. Morton¹⁷,
- 9 John E. Mayer Jr¹⁸ Christine E. Seidman^{19,20}, Jonathan G. Seidman¹⁹, Yufeng Shen²¹,
- 10 Michael Wagner²², H. Joseph Yost²³, Mark Yandell^{1*}, and Martin Tristani-Firouzi^{24,*}
- 11
- ¹Department of Human Genetics, University of Utah, Salt Lake City, UT, 84112, USA.
- ¹³ ²Department of Biomedical Informatics, University of Utah, Salt Lake City, UT, 84108,
- 14 USA.
- ³Department of Pediatrics, Maine Medical Center, Portland, ME, USA.
- 16 4Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, 84112,
- 17 USA;
- ⁵Pediatric Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah, USA
- ⁶Fabric Genomics Inc., Oakland, CA, 94612, USA
- ⁷Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA 94305,
 USA.
- ⁸Department of Surgery, University of California, San Francisco, CA 94143, USA
- ⁹Department of Pediatrics, Yale University School of Medicine, New Haven, CT, 06416,
 USA.
- ¹⁰Department of Genetics, Yale University School of Medicine, New Haven, CT, 06416,
- 26 USA.
- ¹¹Departments of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston,
 MA 02115, USA.
- ¹²Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA,
 USA.
- ¹³Mindich Child Health and Development Institute, Departments of Pediatrics and Genetics
- 32 & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029,
- 33 USA.

- ¹⁴Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania,
- 35 Philadelphia, Pennsylvania, USA.
- ¹⁵Department of Surgery, Yale University, New Haven, CT, USA.
- ¹⁶Department of Cardiology, Boston Children's Hospital, and Department of Pediatrics,
- 38 Harvard Medical School, Boston, MA 02115, USA.
- ³⁹ ¹⁷Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital,
- 40 Boston, MA, USA
- 41 ¹⁸Department of Cardiovascular Surgery, Boston Children's Hospital, Boston, MA 02115,
- 42 USA
- 43 ¹⁹Departments of Genetics and Medicine, Harvard Medical School, Boston 02115, USA.
- ⁴⁴ ²⁰Howard Hughes Medical Institute, Harvard Medical School, Boston 02115, USA.
- 45 ²¹Departments of Systems Biology and Biomedical Informatics, Columbia University, New
- 46 York, NY 10032, USA.
- 47 ²²Division of Biomedical Informatics, Department of Pediatrics, Cincinnati Children's
- 48 Hospital Medical Center, Cincinnati, OH, USA.
- 49 ²³Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA.
- ⁵⁰ ²⁴Nora Eccles Harrison Cardiovascular Research and Training Institute, and Division of
- 51 Pediatric Cardiology, Salt Lake City, Utah, 84108, USA.
- 52
- 53 email: scott.watkins@genetics.utah.edu, edgarh@genetics.utah.edu,
- 54 Thomas.A.Miller@mainehealth.org, Nathan.Blue@hsc.utah.edu,
- 55 RAQUEL.REISINGER@hsc.utah.edu, Eric.Griffiths@hsc.utah.edu,
- 56 efrise@fabricgenomics.com, danb@stanford.edu, marko.boskovski@ucsf.edu,
- 57 martina.brueckner@yale.edu, wendy.chung@childrens.harvard.edu,
- 58 GAYNOR@chop.edu, bruce.gelb@mssm.edu, peter.gruber@yale.edu,
- 59 GOLDMUNTZ@email.chop.edu, jane.newburger@cardio.chboston.org,
- 60 Amy.Roberts@cardio.chboston.org, sarah.morton@childrens.harvard.edu,
- 61 John.Mayer@cardio.chboston.org, cseidman@genetics.med.harvard.edu,
- 62 seidman@genetics.med.harvard.edu, ys2411@columbia.edu, Michael.Wagner@cchmc.org,
- 63 jyost@genetics.utah.edu, myandell@genetics.utah.edu, and Martin.Tristani@utah.edu
- 64
- 65 *Corresponding authors

66 Abstract

67 While genome sequencing has transformed medicine by elucidating the genetic underpinnings 68 of both rare and common complex disorders, its utility to predict clinical outcomes remains 69 understudied. Here, we used artificial intelligence (AI) technologies to explore the predictive 70 value of genome sequencing in forecasting clinical outcomes following surgery for congenital 71 heart defects (CHD). We report results for a cohort of 2,253 CHD patients from the Pediatric 72 Cardiac Genomics Consortium with a broad range of complex heart defects, pre- and post-73 operative clinical variables and exome sequencing. Damaging genotypes in chromatin-74 modifying and cilia-related genes were associated with an elevated risk of adverse post-75 operative outcomes, including mortality, cardiac arrest and prolonged mechanical ventilation. 76 The impact of damaging genotypes was further amplified in the context of specific CHD 77 phenotypes, surgical complexity and extra-cardiac anomalies. The absence of a damaging 78 genotype in chromatin-modifying and cilia-related genes was also informative, reducing the risk 79 for adverse postoperative outcomes. Thus, genome sequencing enriches the ability to forecast 80 outcomes following congenital cardiac surgery.

82 Introduction

83 Congenital heart defects (CHD) represent a complex class of often life-threatening disorders that 84 affect more than 40,000 newborns in the U.S. annually. The prevalence of CHD is approximately 85 1 per 100 live births, with an incidence that varies according to the specific CHD lesion¹⁻³. The genetic architecture of CHD has been the focus of several large-scale sequencing efforts⁴⁻⁹, 86 87 demonstrating that the genetic landscape of syndromic and sporadic CHD differ, with sporadic 88 forms characterized by considerable locus and allelic heterogeneity⁷. More recently, work by the 89 National Heart, Lung and Blood Institute (NHLBI)-funded Pediatric Cardiac Genomics 90 Consortium (PCGC) has shown that dominantly and recessively inherited forms of CHD have 91 distinct genetic and phenotypic landscapes, whereby dominant forms of CHD are significantly 92 enriched for damaging variants in chromatin-modifying genes, while recessive forms are enriched 93 for damaging variants in cilia-related biallelic genotypes and heterotaxy phenotypes^{4,5,8,9}.

94 Recent work has also demonstrated the value of genetic testing for outcomes prediction for specific types of CHD and within specific clinical contexts¹⁰⁻¹⁴. Broader investigations, 95 96 however, have faced difficulties in assaying genetic contributions across multiple CHD 97 phenotypes and clinical contexts, in part due to the widely varying severity of CHD lesions and 98 the complex medical and surgical interventions necessary for survival. Here, we demonstrate that 99 condensing heterogenous CHD phenotypes into five major clinically relevant phenotypic 100 categories using anatomic descriptors¹⁵ renders these data amenable for outcomes analyses. We 101 also show that the high allelic and locus heterogeneity characteristic of CHD can be overcome 102 using an artificial intelligence (AI) genome interpretation tool¹⁶, followed by categorization of 103 damaging genotypes into molecular pathways or gene categories. This two-pronged approach of 104 phenotypic and genotypic classification, when combined with probabilistic graphical models,

enables clinically relevant and highly personalized risk estimates in patients undergoing congenitalcardiac surgery.

107 Methods

108 Human subjects. All patients were diagnosed, phenotyped, and recruited by PCGC centers and 109 participating regional hospitals into the PCGC Congenital Heart Disease Network Study (CHD 110 GENES: ClinicalTrials.gov identifier NCT01196182; [https://clinicaltrials.gov/]). Informed 111 consent was obtained from all participants or the participants' guardians. Approval for human 112 subjects research was obtained by the institutional review boards of participating centers, 113 including Boston's Children's Hospital, Brigham and Women's Hospital, Great Ormond Street 114 Hospital, Children's Hospital of Los Angeles, Children's Hospital of Philadelphia, Columbia University 115 Medical Center, Icahn School of Medicine at Mount Sinai, Rochester School of Medicine and 116 Dentistry, Steven and Alexandra Cohen Children's Medical Center of New York, Lucile Packard 117 Children's Hospital Stanford, University of California-San Francisco, University of Utah, and Yale 118 School of Medicine. Automated CHD phenotype classification was performed on 14,765 PCGC 119 participants. A subset of these participants who had both exome sequencing and perioperative 120 data (2,253) was used for network analyses.

121

122 **Clinical phenotypes.** Cardiac diagnoses were obtained from review of echocardiogram, cardiac 123 MRI, catheterization, and operative reports at the time of enrollment into the PCGC^{4,5}. Detailed 124 cardiac diagnoses for each patient were coded using the Fyler system¹⁵. Extra-cardiac anomalies 125 (ECAs) were identified at the time of PCGC enrollment^{4,5} (Supplemental Table 1). Any 126 structural anomaly that was not acquired was classified as an extra cardiac anomaly (ECA).

128 **Post-operative variables.** For patients undergoing open heart surgery, surgical and 129 hospitalization data were obtained from participating centers using the local data collected for 130 submission to the Society of Thoracic Surgeons Congenital Heart Surgery Database (STS-131 CHSD)¹⁷. A total of 59 surgical complication variables were extracted for analysis. The size of 132 the final data set was constrained to 2,253 patients, such that all patients had WES and surgical variables had no more than 10% missing data. Most patients had multiple cardiac surgeries. A 133 134 patient was scored as having an adverse event or surgical complication (e.g., prolonged 135 mechanical ventilation) if that event occurred for any surgery at any age (Supplemental Table 136 2).

137

Surgical complexity. Surgical complexity is a well-known driver of mortality and morbidity.
In response, the STS-European Association for Cardio-Thoracic Surgery (STAT) has created
risk assessment categories in which procedures are grouped based on similar mortality rates¹⁸.
STAT categories range from 1 to 5, with STAT1 representing the procedures with the lowest
mortality rates and STAT5 representing the procedures with the highest mortality rates.

143

144 CHD classification. The PCGC has classified cardiac diagnoses for over 14,000 CHD probands 145 using the Fyler coding system, which describes the congenitally malformed heart using a 146 vocabulary of more than 3,000 possible phenotypic descriptors¹⁵. While this system allows for 147 highly granular descriptions of heart defects, we hypothesized that condensing these terms into a few 148 clinically relevant phenotypic categories might render them more tractable for outcomes analyses. 149 Thus, we sought to automate cardiac phenotype classification across the entire PCGC cohort, 150 assigning each patient to a single category. To do so, we used five major cardiac categories derived 151 from a previous PCGC study⁵: left ventricular outflow tract obstructions (LVO), laterality and

heterotaxy defects (HTX), atrioventricular canal defects (AVC), conotruncal defects (CTD), and other defects (OTH), which includes simple atrial septal defects and more complex heart defects not assigned to the other four categories^{5,15}. Each participant was assigned uniquely to one of the five phenotypic categories.

156 A gradient-boosted decision tree model was built to automatically classify PCGC 157 probands (14,765) into one of these five CHD categories (see Supplemental Methods, 158 Supplemental Figures 1, 2). Model learning and classification was performed using an ensemblebased method using the XGBoost library $(v1.5)^{19}$. We created an analysis toolkit to streamline 159 160 XGBoost training, grid-based parameter optimization, and performance evaluation. The truth set 161 for training the classifier included 3,000 CHD patients, 2,752 PCGC patients previously assigned 162 into the five CHD categories⁵ and 248 randomly selected PCGC patients that were manually 163 reviewed and assigned to a CHD phenotype category. A gradient-boosted probabilistic patient classifier was built with XGBoost¹⁹ using the 3,000 patients and 698 Fyler features 164 165 (Supplemental Table 3). Model training was performed with five-fold cross-validation and 166 replacement subsampling (Supplemental Table 4). Model accuracy was assessed by comparing the patient's known phenotype category label derived from the literature⁵ to its predicted 167 168 phenotype category label (Supplemental Figure 3, Supplemental Table 5). Single-class 169 prediction accuracy for the training data was higher for HTX (98.9%), AVC (97.8%), and LVO 170 (97.7%) than for CTD (95.3%) and OTH (91.9%), where a low level of ambiguity occurred. 171 Overall classification accuracy was 97.7% with a specificity of 99.3%, and sensitivity of 172 97.7% (Supplemental Tables 6). We then applied the trained classifier to 14,765 PCGC CHD 173 patients with Fyler descriptors (Supplemental Tables 7, 8). Final classification of the 3,000 174 training patients was identical to the original training predictions. The five phenotype categories remained generally proportional between the training data and the full data set, with a maximum 175

176 observed difference of 4.2% for CTD patients.

177

178 AI-based scoring of predicted damaging genetic variants. AI-based identification of 179 candidate disease-causing genotypes was performed using Fabric GEM¹⁶ (Fabric Genomics, 180 Oakland, CA). GEM incorporates Human Phenotype Ontology (HPO) terms, sex, genotype 181 frequency (gnomAD), evolutionary conservation, Online Mendelian Inheritance in Man 182 (OMIM), GnomAD, and ClinVar information in a probabilistic AI framework to identify the 183 most likely genetic variant or genotype that explains the patient's disease phenotype. Because 184 WES are difficult substrates for CNV calling, we restricted our analyses to SNVs and short 185 indels. HPO terms utilized in the GEM analyses were based on each patient's Fyler phenotypes, 186 which were mapped to HPO terms using the Clinithink software package (Clinithink, London).

GEM's gene scores are log₁₀ transformed Bayes factors²⁰ that summarize the relative 187 188 support for the hypothesis that the prioritized genotype damages the gene in which it resides and 189 explains the patient's phenotype versus the hypothesis that the variant neither damages the gene 190 nor explains the patient's phenotype. We used a stringent GEM score of ≥ 1.0 to represent a likely pathogenic genotype. A recent genomic analysis of critically ill newborns¹⁶ showed that 191 192 a GEM score of ≥ 1.0 identified 90% of all true positive damaging variants, with a median of 193 two candidate variants per patient¹⁶. Gene penetrance for GEM calculations was set to 0.95 to 194 enforce strict consideration of known dominant and recessive disorders. For downstream 195 analyses, damaging genetic variants were classified as *de novo*, dominant, or recessive/biallelic 196 variants based on their inheritance pattern in trios. Dominant and *de novo* damaging variants 197 were required to have a frequency of < 1/10000 in gnomAD databases (v2.1, v3.1) and most 198 variants were not observed. Overall, we identified damaging *de novo* or recessive genotypes in 199 10.56% of the study cohort (Supplemental Tables 9, 10), in line with previous studies that utilized

different methods of defining pathogenicity^{4,5,8,9}. Damaging genetic variants were assigned to several functional gene pathways. Gene lists for gene pathways were obtained using the reactome pathway browser. Gene lists are shown in Supplemental Table 11 and have been previously described^{5,8,9} There is overlap between gene lists, with some genes represented in more than one gene pathway/category (Supplemental Figure 4).

205

206 **Probabilistic graphical models.** Probabilistic graphical models (PGMs) provide a robust 207 explainable AI methodology capable of discovering and quantifying additive and synergistic 208 effects amongst broad classes of variables. For the work presented here, we used a form of PGMs 209 known as a Bayesian networks²¹. Bayesian networks are fully transparent, and their graphical 210 representation offers an intuitive and visual mechanism for understanding the relationships 211 between variables and the impacts of multiple variables on outcomes of interest²²⁻²⁹. Moreover, 212 Bayesian networks offer practical advantages over regression approaches, by capturing the entire 213 joint probability distribution of the data, encompassing all interrelationships among the variables 214 incorporated in the non-linear model. Thus, a single network can be used to explore any 215 combination of variables as a target outcome in one query and then as a risk factor for a different 216 target outcome, all within the same model. For more on these points see 21,30,31.

217

Feature selection. Single variables, such as damaging genetic variants in chromatin-modifying genes, were tested for conditional dependency with phenotype variables using exact Bayesian Networks. Each conditional probability [e.g., the probability of LVO given a damaging *de novo* chromatin variant: P (LVO | *chromatin dGV*) was estimated as the median conditional probability from 1000 independent networks. Conditional probability estimates were divided by the baseline probability for each respective phenotype to obtain absolute risk ratios. Associations

with absolute risk ratios ≥ 1.0 were selected for further analyses. Surgery-related variables associated with gene categories and CHD phenotypes were identified in a similar way. Each surgical feature was tested individually as a conditional variable with genetic variables and each of the five specific CHD phenotypes. All conditional variables, individually or as composite variables (e.g., mortality and ECA), were required to have at least six events.

229

230 Network construction. Bayesian networks were created for each CHD phenotype category. 231 Each network included genetic and surgical variables identified in the feature selection stage. 232 All-cause mortality was also included in each network. All input conditional variables were coded 233 as presence/absence. A small number of missing surgical values (< 10% for any single variable) 234 was imputed using a K-nearest neighbors approach (k = 10). The structure of each network was 235 learned with the Silander-Myllymaki exact algorithm with Bayesian information criterion (BIC) 236 scoring³² or by a greedy hill-climbing method for the large networks with more than 15 nodes. 237 Posterior probabilities were network propagated using exact inference. Network structure 238 learning and belief propagation were performed with the bnstruct and gRain R packages^{33,34}. 239 To improve convenience and functionality, we created the BayesNetExplorer.jl package which 240 implements network structure learning and belief propagation methods and provides tools for 241 feature selection, risk estimation, graphics, and other network analysis tasks.

242

Risk Calculations. We used two risk ratios (RR) to summarize our risk estimates, absolute and relative RR. For example, the absolute RR of a LVO phenotype given a damaging genotype in a chromatin-modifying gene is as follows: *Absolute* $RR_{LVO|dGVchromatin} =$ $\frac{P(LVO = true | dGV chromatin=true)}{P(LVO = true)}$. The relative RR estimates the relative change in mortality risk

for LVO patients with damaging mutations in chromatin-modifying genes, compared to similar

248 patients without a damaging chromatin genotype: Relative $RR_{mortality + LVO \mid dGV chromatin} =$

249 $\frac{P(mortality = true,LVO = true | dGV chromatin = true)}{P(mortality = true,LVO = true | GV chromatin = false)}$ Final risk ratios and their confidence intervals 250 are reported as the median and 95% confidence interval from an empirical distribution of risk ratio 251 estimates. The empirical distributions are created by randomly resampling the data set with 252 replacement and recreating 1000 independent networks and risk estimates. A Laplace correction 253 (k = 1) or network smoothing value was used to prevent zero-state probability estimates during 254 bootstrapping.

255

256 **Results**

257 **Refining the genetic architecture of CHD.** For genetic and outcomes analysis, the study 258 population consisted of 2,253 PCGC probands (1992 trios, 12 duos, 245 singletons) with both 259 exome sequencing and surgical outcomes data, classified into five CHD phenotype categories. The AI-based genome analysis tool GEM¹⁶ identified predicted damaging *de novo* genotypes in 260 261 238 participants (10.6% of the cohort). A total of 131 damaging de novo / dominant and 198 262 damaging recessive/biallelic genetic variants were discovered (Supplemental Tables 9, 10). 263 There were 17 genes with damaging de novo variants in two or more patients. The most 264 commonly recurrent de novo variants were in known CHD-related genes such as KMT2D (11), 265 CHD7 (6), RAF1 (3), JAG1 (3), and TAB2 (3). Biallelic damaging genotypes were observed in 266 multiple patients for several genes including DYNC2H1 (3), DNAH5 (3), LAMA2 (3), GDF1 (2), 267 and IFT140 (2).

We discovered that CHD phenotype categories were enriched for damaging genetic variants in specific gene pathways/categories (Table 1). For example, the LVO class was enriched 1.61-fold (CI 1.41-1.81) for damaging *de novo* genotypes in chromatin-modifying

271 genes, with this signal driven primarily by patients with hypoplastic left heart syndrome 272 (HLHS), a subset of LVO where these genotypes were enriched 1.92-fold (CI 1.32-2.52). While 273 previous studies implicated damaging chromatin-modifying gene variants in CHD cohorts at 274 large^{4,5,8,9}, our analyses here help to define the specific CHD subtypes most influenced by 275 damaging variants in chromatin-modification genes. The LVO phenotype class was also 276 enriched for de novo genotypes in WNT genes (2.13-fold, CI 1.86-2.40), signal transduction 277 genes (1.51-fold, CI 1.01-2.01), and a curated list of genes known to cause CHD (1.22-fold, CI 278 1.11-1.33; see Supplemental Tables 9 and 10). Notably, damaging genotypes in these pathways 279 were not enriched in HLHS patients, further underscoring the complex genetic landscape 280 underlying CHD.

The HTX phenotype class was enriched for damaging recessive/biallelic variants in ciliarelated genes (2.63-fold, CI 2.06-3.20) and showed proportionally higher enrichment in the subset of motile cilia genes modulated by FOXJ1 (6.89-fold, 3.30-10.36), findings consistent with previous reports^{5,8,35}. The OTHER phenotype class was enriched for damaging *de novo* variants in chromatin-modifying genes (1.85-fold, CI 1.44-2.26) and the curated CHD genes (1.59-fold, CI 1.38-1.80) lists. We were underpowered to detect enrichment in damaging genotypes in the AVC and CTD phenotype classes.

288

289 Damaging genotypes impact surgical outcomes.

To further explore the relationships between genetic and clinical variables, we utilized Bayesian networks, a powerful statistical framework that can model complex dependencies, including non-linear relationships and indirect associations, in a probabilistic manner. In Bayesian networks, variables are depicted as nodes in a graph and conditional dependencies between variables are represented by the edges connecting those nodes. Once a network is constructed,

the impact of any combination variables on any selected outcome can be quantified, while controlling for the effects of other variables incorporated into the network. The networks describing the conditional dependencies between damaging genotypes, CHD phenotypes and post-operative variables are shown in Figure 1a, b.

299 Damaging genotypes in chromatin-modifying and cilia-related genes (defined by a 300 GEM^{16} score > 1.0) increased the probability of severe adverse clinical outcomes following 301 congenital cardiac surgery, including mortality, cardiac arrest, and prolonged mechanical 302 ventilation (> 7 days post-surgery). For example, damaging *de novo* chromatin genetic variants 303 increased the probability (relative risk) of mortality 1.81-fold (CI 1.50-3.21), cardiac arrest 1.74-304 fold (CI 1.40-2.94) and prolonged ventilation 1.65-fold (CI 1.41-2.27). Likewise, damaging 305 recessive/biallelic cilia genotypes increased the probability of mortality 1.40-fold (CI 1.09-306 2.10), cardiac arrest 1.50-fold (CI 1.13-2.34) and prolonged ventilation 1.43-fold (CI 1.09-1.96). 307 Reciprocally, the absence of a damaging genotype was protective for these adverse post-308 operative outcomes. Thus, for a proband without a damaging *de novo* chromatin genotype, the 309 relative risk ratio for mortality was 0.55 (CI 0.31-0.69), 0.58 (CI 0.34-0.72) for cardiac arrest 310 and 0.61 (CI 0.44-0.72) for prolonged ventilation. For a proband without at damaging 311 recessive/biallelic cilia genotype, the relative risk ratio for mortality was 0.72 (CI 0.48-0.91), 312 0.63 (CI 0.43-0.88) for cardiac arrest and 0.70 (CI 0.51-0.92) for prolonged ventilation.

313

314 Damaging genotypes impact surgical outcomes in the context of surgical mortality risk 315 category.

We discovered that damaging chromatin and cilia genotypes were associated with an increased risk of mortality for probands undergoing the highest risk surgical procedures (Figure 1c). Thus, probands who died after a STAT4 or STAT5 surgical procedure were 1.80-fold (CI

319 1.47-4.13) more likely to harbor a damaging chromatin variant. Similarly, those who died after 320 a STAT4 surgery were 1.73-fold (CI 1.24-2.47) more likely to harbor a damaging 321 recessive/biallelic cilia genotype (Figure 1). Damaging chromatin and cilia genotypes were 322 overrepresented in probands experiencing cardiac arrest or prolonged mechanical ventilation 323 following the most complex surgical procedures (Figure 1c).

324

325 Damaging genotypes impact surgical outcomes in the context of CHD phenotypes

326 More broadly, considering mortality in the context of CHD phenotypes, LVO patients 327 who died were 2.26-fold (CI 1.22-2.94) more likely to harbor a damaging de novo chromatin 328 genotype, while HTX patients who died were 2.80-fold (CI 2.45-3.15) more likely to harbor a 329 damaging recessive/biallelic cilia genotype (Figure 1c). Similarly, damaging chromatin or cilia 330 genotypes were overrepresented in probands with LVO, HLHS and HTX who experienced 331 cardiac arrest or prolonged post-operative ventilation (Figure 1c). Specifically, HTX patients 332 who arrested post-operatively were 3.34-fold (CI 1.44-5.49) more likely to harbor a damaging 333 recessive/biallelic cilia genotype, compared to similar patients without a damaging cilia 334 genotype. Collectively, these findings demonstrate that genome sequencing data are critical for 335 predicting severe post-operative events in the context of specific CHD phenotypes and the 336 highest risk congenital heart surgeries.

337

338 Damaging genotypes impact surgical outcomes in the context of extracardiac phenotypes.

339 Given the recognized impact of ECAs on outcomes following congenital cardiac 340 surgery^{10,14,36}, we also explored the relationship between ECAs and adverse post-operative 341 outcomes in the context of genotypes and CHD phenotypes. ECAs increased the probability

(relative risk) of mortality 2.85-fold (CI 1.47-2.86) and prolonged ventilation 1.72-fold (CI 1.631.72) following congenital cardiac surgery. Consistent with previous findings¹⁰, damaging *de novo* genetic variants, including *de novo* variants in chromatin-modifying genes, were enriched in
probands with ECAs 1.47-fold (CI 1.44-1.48) and 2.09-fold (CI 2.08-2.11), respectively. By
contrast, damaging recessive/biallelic cilia genotypes were not enriched in probands with ECAs
(0.84-fold; CI 0.85-1.13).

348 We also examined reciprocal effects, i.e., impact of predicted damaging genotypes on 349 ECAs and adverse outcomes. For example, probands with damaging *de novo* chromatin genotypes 350 identified by GEM were 2.49-fold (CI 2.17-4.99) more likely to have an ECA and die, compared 351 to probands without a damaging chromatin genotype, and 2.44-fold (CI 1.97-3.41) more likely to 352 have an ECA and prolonged ventilation (Figure 2). Moreover, a damaging recessive/biallelic cilia 353 genotype identified by GEM increased the probability of mortality in probands with an ECA 1.48-354 fold (CI 1.02-2.85), compared to similar probands without a damaging cilia genotype, and 355 increased the probability of prolonged ventilation in the presence of an ECA 1.52-fold (CI 1.06-356 2.51). Additionally, a damaging cilia genotype increased the probability of prolonged ventilation 357 in HTX patients with an ECA 4.01-fold (CI 1.67-10.6), compared to similar patients without a 358 damaging cilia genotype (Figure 2). Taken together, these findings demonstrate that damaging 359 genotypes in chromatin and cilia genes predict severe post-operative events in the setting of 360 ECAs.

The number of probands experiencing adverse outcomes and harboring damaging gene pathway variants in the AVC, CTD, and OTHER categories was too low to warrant generation of Bayesian networks for outcomes prediction in these CHD phenotypes. Consequently, larger cohorts are necessary to adequately predict the impact of genetics on outcomes for these CHD phenotypes. However, damaging genotypes in a number of gene pathways/categories,

such as FOXJ1-controlled genes, high murine heart expression genes (HHE), WNT signaling genes, NOTCH signaling genes, and genes in a curated CHD gene list were predictive of mortality for the most complex surgical categories (Figure 3). Damaging genotypes in signal transduction and TGF- β pathways were not predictive of mortality. Taken together, these findings highlight the value of genomic data for predicting adverse outcomes following congenital cardiac surgery, especially in the context of CHD phenotypes, ECAs and surgical complexity.

373

374 **Discussion**

375

376 Assessing the impact of genetics on patient outcomes in CHD is complicated by the intrinsic 377 severity of the cardiac lesion, the complex medical and surgical interventions necessary for 378 survival, and the high degree of phenotypic, locus and allelic heterogeneity. The NHBLI-funded 379 PCGC is one of the world's largest collections of genetic, phenotypic, and clinical variables for 380 CHD and thus provides an excellent resource for exploring the utility of genomics data for 381 outcomes prediction. In this study, we implemented an explainable AI-based analysis 382 framework to automatically classify CHD patients into phenotype categories and identify 383 damaging genetic variants and genotypes. This approach allowed us to explore how damaging 384 genotypes impact outcomes following congenital cardiac surgery, in the context of specific CHD 385 phenotypes, ECAs, and surgical complexity, providing precise risk estimates for specific clinical 386 contexts.

387 *De novo* variants associated with CHD have been shown to be enriched in genes related 388 to chromatin regulation^{4,5,8,9}. Our results identify LVO lesions and confirm HLHS as a principal 389 driver of the chromatin signal in this cohort. HLHS is one of the most severe forms of CHD and

390 associated with substantial morbidity and mortality. Our results show that the subset of HLHS 391 patients with damaging genetic variants in chromatin genes has even greater risk (up to 2.57-392 fold) for severe post-operative outcomes in the context of the most complex surgical procedures. 393 Our findings also reinforce previous studies showing that damaging recessive/biallelic 394 genotypes in cilia-related genes are overrepresented in the heterotaxy/laterality phenotype 395 category^{5,8}. Our results here demonstrate the additional utility of genetic findings for outcomes 396 predictions. Damaging recessive/biallelic cilia genotypes increase the risk of severe adverse 397 post-operative outcomes in the context of surgical complexity, HTX phenotype and the presence 398 of an ECA. For example, damaging recessive/biallelic cilia genotype substantially increase 399 (4.01-fold) the risk of prolonged ventilation for HTX patients with an ECA. These findings are 400 consistent with an emerging body of literature implicating cilia dysfunction, HTX, and 401 respiratory complications following congenital cardiac surgery^{37,38}.

402 Established and emerging literature has highlighted the impact of genetics on mortality 403 and other adverse outcomes following congenital cardiac surgery, mostly focusing on the impact 404 of copy number variants.¹⁰⁻¹⁴ Damaging *de novo* genic variants were associated with worse 405 transplant-free survival and longer times to final extubation in a previously reported subset of 406 the PCGC cohort (n = 1268)¹⁰. Here, we expand upon these findings in the largest study to date 407 relating genotypes to CHD surgical outcomes. Our analyses reveal that damaging genotypes in 408 specific gene pathways/categories impact post-operative outcomes across CHD phenotypic 409 categories in specific and quantifiable ways.

410 Our AI approach allowed us to unravel the conditional dependencies among diverse 411 clinical and genetic variables and to discover their impacts, either in isolation or in combination, 412 on post-operative outcomes. These findings define a critical role for genome sequencing in 413 outcomes prediction for congenital cardiac surgeries, especially in the context of higher risk

414 surgical procedures, specific CHD phenotypes and ECAs. Importantly, the absence of damaging 415 genotypes was protective for adverse outcomes following congenital cardiac surgery. Thus, 416 genomic information is informative whether or not a proband has an identified damaging 417 genotype.

418 Nevertheless, there are limitations inherent to this study. For example, the PCGC 419 population is not an inception cohort and thus is likely depleted for genetic lesions that 420 predispose to early death, meaning our morbidity estimates are likely lower bounds. Although 421 the PCGC cohort reflects a broad spectrum of CHD, recruitment of severe CHD forms was 422 favored, leaving us under-powered to investigate the impact of genome sequencing for less 423 severe CHD phenotypes. Additionally, while large clinical registries, such as the STS database, 424 are invaluable resources for outcomes research, these databases, despite the inclusion of auditing 425 features, may suffer from data quality issues, variability in the abstraction of data, batch effects, 426 and missing data³⁹⁻⁴¹ that might impact the interpretation of the results presented here. Finally, 427 we do not yet have access to an independent validation cohort with genomic data and similar 428 clinical variables.

429 Looking to the future, a more complete description of the genetic and outcomes 430 landscape of CHD could be enabled through clinical genome sequencing of CHD patients at 431 even greater scales, together with initiatives by major consortia to collect and distribute genomic 432 and clinical data more broadly. Given the rapid decline in costs, the increasing availability and 433 quick turn-a-round time, genome sequencing is now poised to become the standard of care for 434 all critically ill newborns.^{42,43} Our findings make it clear that genome sequencing of all 435 newborns with complex CHD will empower personalized risk-stratification for outcomes 436 following congenital cardiac surgery.

438 Acknowledgments

439

440 We thank the patients and their families for participating in the Pediatric Cardiac Genomics 441 Consortium and Bench to Bassinet research programs. This research would not be possible 442 without the clinical professionals involved in patient recruitment, and we thank those at the 443 following institutions including the Columbia Medical School: D. Awad, C. Breton, K. Celia, C. 444 Duarte, D. Etwaru, N. Fishman, E. Griffin, M. Kaspakoval, J. Kline, R. Korsin, A. Lanz, E. 445 Marquez, D. Queen, A. Rodriguez, J. Rose, J.K. Sond, D. Warburton, A. Wilpers, and R. Yee; 2) 446 the Children's Hospital of Los Angeles: J. Ellashek and N. Tran; 3) the Children's Hospital of 447 Philadelphia: S. Edman, J. Garbarini, J. Tusi, and S. Woyciechowski; 4) the Harvard Medical 448 School: J. Geva and M. Borensztein; 5) the Icahn School of Medicine at Mount Sinai: A. Julian, 449 M. Mac Neal, Y. Mendez, T. Mendiz-Ramdeen, and C. Mintz; 6) the University College London: 450 B. McDonough, K. Flack, L. Panesar, and N. Taylor; 7) the University of Rochester School of 451 Medicine and Dentistry: E. Taillie; and 8) the Yale School of Medicine: N. Cross. We thank 452 Nick Felicelli, Prakash Velayutham, and the staff at the Cincinnati Children's Hospital Medical 453 Center for computational support and for providing access to the HeartsMart database. We thank 454 Carson Holt, Shawn Rynearson, Barry Moore at the Utah Center for Genomic Discovery and the 455 staff at the Utah Center for High Performance Computing for high-throughput processing of 456 patient sequence data.

457

458 The Pediatric Cardiac Genomics Consortium (PCGC) program is funded by the National Heart, 459 Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human 460 Services through grants UM1HL128711, UM1HL098162, UM1HL098147, UM1HL098123, 461 UM1HL128761, U01-HL098153, U01-HL098163, and U01HL131003. This manuscript was 462 prepared in collaboration with investigators of the PCGC and has been reviewed and/or 463 PCGC. approved by the PCGC investigators are listed at 464 [https://benchtobassinet.com/?page_id=119]

465 Data availability

- 466 Genetic and phenotypic data used in the paper are provided in the supplementary tables. Exome
- 467 sequencing data have been deposited in the database of Genotypes and Phenotypes (dbGaP)
- 468 under accession numbers <u>phs000571.v1.p1</u>, <u>phs000571.v2.p1</u> and <u>phs000571.v3.p2</u>.

469

470 **Online resources**

- 471 <u>https://heartsmart.pcgcid.org/</u>
- 472 <u>https://github.com/dmlc/XGBoost.jl</u>
- 473 <u>https://github.com/ScottWatkins/BayesNetExplorer</u>
- 474 <u>https://julialang.org/</u>
- 475 <u>https://www.r-project.org/</u>
- 476 <u>https://reactome.org</u>
- 477

478 Author contributions

- 479 W.S.W., E.J.H., M.Y., and M.T.F. conceived and planned the project; M.T.F. and W.S.W.
- 480 analyzed the data and created the manuscript; E.J.H., R.Z., advised the network analysis and
- 481 presentation; T.A.M. provided clinical interpretation and analysis support; E.F. contributed to
- the GEM implementation; M.T.F. and M.Y. oversaw all aspects of the network and statistical
- 483 analyses; M.W. provided network access to data; W.S.W., E.J.H., T.A.M., R.Z., D.B., M.B.,
- 484 W.K.C., J.W.G., B.D.G., E.G., P.G., J.W.N., S.U.M., A.E.R., C.E.S., J.G.S., Y.S., H.J.Y.,
- 485 N.R.B., E.R.G., M.T.B, J.E.M., M.Y., and M.T.F. edited the final manuscript.
- 486

487 **Competing interests**

- 488 The authors declare the following competing interests: M.Y. -- GEM commercialization through
- 489 Fabric Genomics, Inc; E.F. is an employee of Fabric Genomics.

491 **References**

- 492
- 493 1. Hoffman, J.I. & Kaplan, S. The incidence of congenital heart disease. *J Am Coll Cardiol*494 **39**, 1890-1900 (2002).
- 495 2. Liu, Y., *et al.* Global birth prevalence of congenital heart defects 1970-2017: updated 496 systematic review and meta-analysis of 260 studies. *Int J Epidemiol* **48**, 455-463 (2019).
- 497 3. Reller, M.D., Strickland, M.J., Riehle-Colarusso, T., Mahle, W.T. & Correa, A. Prevalence
 498 of congenital heart defects in metropolitan Atlanta, 1998-2005. *J Pediatr* 153, 807-813
 499 (2008).
- 5004.Homsy, J., et al. De novo mutations in congenital heart disease with neurodevelopmental501and other congenital anomalies. Science 350, 1262-1266 (2015).
- 502 5. Jin, S.C., *et al.* Contribution of rare inherited and *de novo* variants in 2,871 congenital heart
 503 disease probands. *Nat Genet* 49, 1593-1601 (2017).
- 6. Richter, F., *et al.* Genomic analyses implicate noncoding de novo variants in congenital
 heart disease. *Nat Genet* 52, 769-777 (2020).
- 506 7. Sifrim, A., *et al.* Distinct genetic architectures for syndromic and nonsyndromic congenital
 507 heart defects identified by exome sequencing. *Nat Genet* 48, 1060-1065 (2016).
- 5088.Watkins, W.S., *et al.* De novo and recessive forms of congenital heart disease have distinct509genetic and phenotypic landscapes. *Nat Commun* 10, 4722 (2019).
- 510 9. Zaidi, S., *et al. De novo* mutations in histone-modifying genes in congenital heart disease.
 511 *Nature* 498, 220-223 (2013).
- 512 10. Boskovski, M.T., *et al.* De Novo Damaging Variants, Clinical Phenotypes, and Post513 Operative Outcomes in Congenital Heart Disease. *Circ Genom Precis Med* 13, e002836
 514 (2020).
- 515 11. Carey, A.S., *et al.* Effect of copy number variants on outcomes for infants with single
 516 ventricle heart defects. *Circ Cardiovasc Genet* 6, 444-451 (2013).
- 517 12. Geddes, G.C., Przybylowski, L.F., 3rd & Ware, S.M. Variants of significance: medical
 518 genetics and surgical outcomes in congenital heart disease. *Curr Opin Pediatr* 32, 730-738
 519 (2020).
- 520 13. Kim, D.S., *et al.* Burden of potentially pathologic copy number variants is higher in children with isolated congenital heart disease and significantly impairs covariate-adjusted transplant-free survival. *J Thorac Cardiovasc Surg* **151**, 1147-1151 e1144 (2016).
- Landis, B.J., *et al.* Learning to Crawl: Determining the Role of Genetic Abnormalities on
 Postoperative Outcomes in Congenital Heart Disease. *J Am Heart Assoc* 11, e026369
 (2022).
- 526 15. Newburger, J.W., Fyler, J. & Colan, S.D. Donald Charles Fyler: 1924-2011. *Cardiol Young* 527 21, 485-489 (2011).
- 528 16. De La Vega, F.M., *et al.* Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases. *Genome Med* 13, 153 (2021).
- 17. Nathan, M., *et al.* Completeness and Accuracy of Local Clinical Registry Data for Children
 Undergoing Heart Surgery. *Ann Thorac Surg* 103, 629-636 (2017).
- Jacobs, M.L., *et al.* Updating an Empirically Based Tool for Analyzing Congenital Heart
 Surgery Mortality. *World J Pediatr Congenit Heart Surg* 12, 246-281 (2021).
- 535 19. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in *Proceedings of* 536 *the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data* 537 *Mining* (Association for Computing Machinery, San Francisco, California, USA, 2016).

- 538 20. Goodman, S.N. Toward evidence-based medical statistics. 2: The Bayes factor. *Ann Intern* 539 *Med* 130, 1005-1013 (1999).
- 540 21. Pearl, J. *Causality : models, reasoning, and inference*, (Cambridge University Press,
 541 Cambridge, U.K.; New York, 2000).
- 542 22. Amann, J., *et al.* Explainability for artificial intelligence in healthcare: a multidisciplinary
 543 perspective. *BMC Med Inform Decis Mak* 20, 310 (2020).
- 544 23. Franz L SY & B., P. A deep learning pipeline for patient diagnosis prediction using
 545 electronic health records. *arXiv preprint* (2020).
- 546 24. Heckerman, D., Geiger, D. & Chickering, D.M. Learning Bayesian Networks: The
 547 Combination of Knowledge and Statistical Data. *arXiv preprint* (2013).
- 548 25. London, A.J. Artificial Intelligence and Black-Box Medical Decisions: Accuracy versus
 549 Explainability. *Hastings Cent Rep* 49, 15-21 (2019).
- 550 26. Miotto, R., Li, L., Kidd, B.A. & Dudley, J.T. Deep Patient: An Unsupervised
 551 Representation to Predict the Future of Patients from the Electronic Health Records. *Sci*552 *Rep* 6, 26094 (2016).
- Payrovnaziri, S.N., *et al.* Explainable artificial intelligence models using real-world
 electronic health record data: a systematic scoping review. *J Am Med Inform Assoc* 27, 1173-1185 (2020).
- Rajkomar, A., *et al.* Scalable and accurate deep learning with electronic health records.
 NPJ Digit Med 1, 18 (2018).
- Wang, H., *et al.* Predicting Hospital Readmission via Cost-Sensitive Deep Learning.
 IEEE/ACM Trans Comput Biol Bioinform 15, 1968-1978 (2018).
- Miller, T.A., *et al.* Genetic, demographic and clinical variables act synergistically to impact
 neurodevelopmental outcomes in children with single ventricle heart disease. *medRxiv*,
 2022.2010.2001.22280594 (2023).
- 31. Wesolowski, S., *et al.* An explainable artificial intelligence approach for predicting
 cardiovascular outcomes using electronic health records. *PLOS Digit Health* 1(2022).
- 565 32. Silander, T. & Myllym[•]aki, P. A Simple Approach for Finding the Globally Optimal
 566 Bayesian Network Structure. *arXiv* 1206.6875 (2012).
- 567 33. Franzin, A., Sambo, F. & Di Camillo, B. bnstruct: an R package for Bayesian Network
 568 structure learning in the presence of missing data. *Bioinformatics* 33, 1250-1252 (2017).
- 569 34. Hojsgaard, S. Graphical Independence Networks with the gRain Package for R. J Stat
 570 Softw 46, 1-26 (2012).
- 571 35. Burnicka-Turek, O., *et al.* Cilia gene mutations cause atrioventricular septal defects by multiple mechanisms. *Human molecular genetics* **25**, 3011-3028 (2016).
- 573 36. Vodiskar, J., *et al.* Impact of Extracardiac Anomalies on Mortality and Morbidity in Staged
 574 Single Ventricle Palliation. *Ann Thorac Surg* 115, 1197-1204 (2023).
- 575 37. Garrod, A.S., *et al.* Airway ciliary dysfunction and sinopulmonary symptoms in patients
 576 with congenital heart disease. *Ann Am Thorac Soc* 11, 1426-1432 (2014).
- 38. Nakhleh, N., *et al.* High prevalence of respiratory ciliary dysfunction in congenital heart
 disease patients with heterotaxy. *Circulation* 125, 2232-2242 (2012).
- 579 39. Kim, K.M., *et al.* The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2022
 580 Update on Outcomes and Research. *Ann Thorac Surg* 115, 566-574 (2023).
- 40. Jacobs, J.P., *et al.* Successful linking of the Society of Thoracic Surgeons Database to
 Social Security data to examine the accuracy of Society of Thoracic Surgeons mortality
 data. *J Thorac Cardiovasc Surg* 145, 976-983 (2013).
- Brown, M.L., Lenoch, J.R. & Schaff, H.V. Variability in data: the Society of Thoracic
 Surgeons National Adult Cardiac Surgery Database. *J Thorac Cardiovasc Surg* 140, 267-

- 586 273 (2010).
- 587 42. Dimmock, D., *et al.* Project Baby Bear: Rapid precision care incorporating rWGS in 5
 588 California children's hospitals demonstrates improved clinical outcomes and reduced costs
 589 of care. *American journal of human genetics* 108, 1231-1238 (2021).
- 590 43. Group, N.I.S., *et al.* Effect of Whole-Genome Sequencing on the Clinical Management of
 591 Acutely III Infants With Suspected Genetic Disease: A Randomized Clinical Trial. *JAMA*592 *Pediatr* 175, 1218-1226 (2021).
- 593
- 594

Table 1. Absolute risk ratios for CHD phenotypes by gene pathway

	n	Cardiac phenotype				
Gene pathway		AVC	CTD	нтх	LVO	ОТН
Chromatin genes (de novo)	28	-	0.52 (0.32, 0.72)	-	1.61 (1.41, 1.81)	1.85 (1.44, 2.26)
Cilia genes (recessive)	35	3.02 (0.00, 6.97)	0.55 (0.41, 0.69)	2.63 (2.06, 3.20)	1.09 (0.90, 1.28)	0.67 (0.18, 1.16)
HHE genes (de novo)	9	-	0.82 (0.00, 1.74)	1.58 (0.00, 9.05)	0.84 (0.00, 4.88)	1.93 (0.00, 4.29)
Wnt genes (de novo)	18	-	0.54 (0.16, 0.92)	-	2.13 (1.86, 2.40)	0.99 (0.00, 2.25)
FoxJ1 genes (recessive)	6	-	0.56 (0.00, 3.54)	6.89 (3.30, 10.36)	0.78 (0.00, 4.82)	0.81 (0.00, 3.54)
Notch1 genes (de novo)	8	-	1.49 (0.96, 2.02)	-	1.36 (0.00, 2.86)	-
Signal trans genes (de novo)	14	3.56 (0.00, 20.50)	0.69 (0.24, 1.14)	-	1.51 (1.01, 2.01)	1.26 (0.00, 2.84)
TGF-β genes (de novo)	13	-	1.11 (0.74, 1.48)	-	1.09 (0.32, 1.86)	1.37 (0.00, 3.05)
CHD genes (de novo)	51	-	0.86 (0.78, 0.94)	0.27 (0.00, 1.43)	1.22 (1.11, 1.33)	1.59 (1.38, 1.80)

Each ratio is reported as the mean and 95% confidence interval from 1000 bootstrap replicates fitted to a t-distribution. Absolute risk ratios with 95% Cls >1.00 are bolded. n indicates the number of patients with damaging genetic variants/genotypes (GEM score \geq 1) found in that gene pathway. Dashes indicate no patients with damaging genotypes. Phenotype categories are atrioventricular canal defects (AVC, n=64), conotruncal defects (CTD, n=934), heterotaxy/laterality defects (HTX, n=219), left ventricular outflow tract obstructions (LVO, n=647), and all other defects (OTH, n=389). HHE, high heart expression genes in the developing mouse heart; CHD genes, a curated list of genes reported to cause CHD (see Supplemental Table 11).

605

606 607

608

609

610

611 612

- - -

- 613 Figure 1. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes in
- 614 the context of CHD phenotypes and surgical complexity.



Figure 2. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes in
 the context of extracardiac anomalies.



Figure 3. Damaging genotypes in various gene categories/pathways are predictive of mortality
 for the most complex surgical procedures.



637 Figure Legends

638

639 Figure 1. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes 640 in the context of CHD phenotypes and surgical complexity. a, An exact Bayesian network 641 depicting the relationship among damaging *de novo* genetic variants in chromatin-modifying genes 642 (green), phenotypes: LVO, HLHS, and ECAs (blue), surgical STAT4 or STAT5 category (red), 643 and surgical outcomes (orange). **b**, An exact Bayesian network depicting the relationship among 644 damaging recessive genetic variants in cilia genes (green), phenotypes: laterality defects (HTX) 645 and extra cardiac anomalies (ECAs) (blue), surgical STAT4 category (yellow), and surgical 646 outcomes (orange). Directed acyclic graphs were moralized and displayed as non-directional 647 networks. c, Relative risk ratios for adverse post-operative outcomes and CHD phenotypes or 648 surgical complexity, comparing probands with and without damaging genotypes. Empirical ninety-649 five percent confidence intervals (CI 5, 95) are based on 1000 resampled network-based 650 probabilities (see Methods). Abbreviations: Chromatin dGV: de novo damaging genotypes in 651 chromatin-modifying genes, LVO: left ventricular outflow tract obstruction, HLHS: hypoplastic 652 left heart syndrome Cilia dGV: biallelic damaging genotypes in cilia-related genes, ECA: extra 653 cardiac anomaly, HTX: heterotaxy/laterality defects, MORT: mortality, STAT4: surgical STAT4 654 category, STAT4-5: surgical STAT 4 or STAT5 category, VENT: post-operative ventilation time >7 655 days.

656

Figure 2. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes
 in the context of extracardiac anomalies. Relative risk ratios for adverse post-operative outcomes
 and extracardiac anomalies (ECAs), comparing probands with and without damaging genotypes in

- 660 chromatin-modifying or cilia-related genes. The \\ symbol represents CI95 that exceeds the x-axis
 661 range.
- 662

663	Figure 3. Damaging genotypes in various gene categories/pathways are predictive of
664	mortality for the most complex surgical procedures. Relative risk ratios for adverse post-
665	operative outcomes and surgical complexity, comparing probands with and without damaging
666	genotypes in various gene pathways or categories. Gene lists are described in Supplemental Table
667	11 and have been previously published. ^{5,8,9} There is overlap between gene lists, with some genes
668	represented in more than one gene pathway/category (Supplemental Figure 4).